HighTide Therapeutics is dedicated to the discovery and development of innovative therapeutics for people suffering from chronic liver diseases, gastrointestinal diseases and metabolic disorders with large and unsatisfied market needs.
SHENZHEN, CHINA and ROCKVILLE, MD, October 1, 2020 — HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company with novel treatments for patientswith non-alcoholic steatohepatitis (NASH) and other chronic liver dis
Chardan Capital Markets will host a Leadership Call with HighTide Therapeutics. The call will be moderated by Michael Morabito, PhD, Senior Research Analyst.
